Seattle Startup Chases Alzheimer’s with $23 Million Series A

Seattle-based AltPep Corporation raised over $23 million in a Series A financing round to take its breakthrough amyloid targeting platform to development. Based on technology developed at the University of Washington, the company is working on three innovations in the fight against Alzheimer’s Disease: early diagnostics, anti-biofilm therapies and coatings, and disease-modifying therapeutics.  AltPep founder and CEO Valerie Daggett commented, “This funding will allow us to build upon our promising preliminary data demonstrating detection of Alzheimer’s disease at its earliest stages and further our preclinical therapeutic program.”

READ THE STORY at BioSpace »